We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.72%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$108M
AUM Growth
-$14.5M
Cap. Flow
-$5.64M
Cap. Flow %
-5.21%
Top 10 Hldgs %
67.6%
Holding
63
New
4
Increased
7
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$736K
2
XOM icon
ExxonMobil
XOM
+$681K
3
CORT icon
Corcept Therapeutics
CORT
+$657K
4
BDSX icon
Biodesix
BDSX
+$497K
5
CSTL icon
Castle Biosciences
CSTL
+$446K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$4.8M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$1.69M
3
PXD
Pioneer Natural Resource Co.
PXD
+$998K
4
BMY icon
Bristol-Myers Squibb
BMY
+$689K
5
OVV icon
Ovintiv
OVV
+$503K

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
2 Energy 5.43%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$28.6M 26.42%
688,218
-15,388
-2% -$689K
BDSX icon
2
Biodesix
BDSX
$209M
$8.7M 8.04%
284,806
+17,392
+7% +$497K
ELUT icon
3
Elutia
ELUT
$42M
$7.7M 7.11%
1,551,655
-103,529
-6% -$336K
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$5.82M 5.37%
42,240
-35,000
-45% -$4.8M
SILK
5
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$4.27M 3.95%
158,094
– –
PRTA icon
6
Prothena Corp
PRTA
$453M
$4.2M 3.88%
203,574
+34,000
+20% +$736K
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.38B
$4.07M 3.76%
250,400
– –
OVV icon
8
Ovintiv
OVV
$16.2B
$3.48M 3.21%
74,200
-10,000
-12% -$503K
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$3.19M 2.94%
10,000
-1,000
-9% -$265K
HROW icon
10
Harrow
HROW
$1.74B
$3.13M 2.9%
150,000
– –
STOK icon
11
Stoke Therapeutics
STOK
$1.81B
$2.84M 2.62%
210,000
– –
PHR icon
12
Phreesia
PHR
$662M
$2.43M 2.25%
114,700
– –
CORT icon
13
Corcept Therapeutics
CORT
$9.72B
$2.4M 2.22%
74,000
+24,000
+48% +$657K
QDEL icon
14
QuidelOrtho
QDEL
$1.19B
$2.25M 2.08%
67,619
+2,416
+4% +$98.8K
MASI
15
DELISTED
Masimo
MASI
$1.92M 1.78%
15,280
– –
FHTX icon
16
Foghorn Therapeutics
FHTX
$305M
$1.85M 1.71%
320,930
– –
ETRN
17
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.73M 1.6%
133,050
– –
PTGX icon
18
Protagonist Therapeutics
PTGX
$9.06B
$1.66M 1.54%
48,000
– –
AXGN icon
19
Axogen
AXGN
$2.12B
$1.43M 1.32%
197,000
+24,000
+14% +$164K
DCGO icon
20
DocGo
DCGO
$64.3M
$1.42M 1.31%
460,000
– –
ALKS icon
21
Alkermes
ALKS
$8.79B
$1.21M 1.11%
50,000
– –
TVTX icon
22
Travere Therapeutics
TVTX
$5.27B
$1M 0.93%
122,000
– –
ATEC icon
23
Alphatec Holdings
ATEC
$1.31B
$920K 0.85%
88,000
– –
CSTL icon
24
Castle Biosciences
CSTL
$733M
$740K 0.68%
34,000
+20,000
+143% +$446K
XOM icon
25
ExxonMobil
XOM
$611B
$673K 0.62%
+5,849
New +$681K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Birchview Capital held 63 positions worth $108M, down 12% from $123M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Birchview Capital withdrew a net $5.64M in Q2 2024, closing 3 positions and reducing 9 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $1.69M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in ExxonMobil worth $673K.

  • Birchview Capital's largest Q2 2024 buy was ExxonMobil: 5,849 shares worth $673K.
  • Birchview Capital added most to Prothena Corp in Q2 2024, an estimated $736K increase.
  • Birchview Capital's biggest Q2 2024 reduction was Neurocrine Biosciences, cutting an estimated $4.8M.
  • Birchview Capital fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $1.69M.
  • Birchview Capital's ten largest holdings make up 68% of its $108M portfolio in Q2 2024.
  • Birchview Capital opened 4 new positions and closed 3 in Q2 2024.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $108M.

Based on Birchview Capital's 13F filing for Q2 2024, filed 13 Aug 2024.